TherapeuticsMDTXMD
About: TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
Employees: 1
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
250% more call options, than puts
Call options by funds: $14K | Put options by funds: $4K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
11% more funds holding
Funds holding: 36 [Q3] → 40 (+4) [Q4]
1.3% more ownership
Funds ownership: 29.31% [Q3] → 30.61% (+1.3%) [Q4]
46% less capital invested
Capital invested by funds: $5.61M [Q3] → $3.03M (-$2.57M) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for TXMD.
Financial journalist opinion
